SCHEMBL6519255

SCHEMBL6519255

NC(=O)Cc1cccc(OCCCN(CC(c2ccccc2)c2ccccc2)C2CCN(CCc3ccccc3)CC2)c1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NR1H3 Q13133 10/20 0.55
CCR5 P51681 1/20 0.48
KCNH2 Q12809 3/20 0.44
KMT2A Q03164 2/20 0.44
OPRM1 P35372 3/20 0.44
NR1H2 P55055 2/20 0.43
MEN1 O00255 1/20 0.43
NR1I2 O75469 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
RXRA P19793 1/20 0.43
VHL P40337 1/20 0.43
RECQL P46063 1/20 0.43
BLM P54132 1/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6512042 0.90 NR1H3 (0.51) NR1H3CCR5KCNH2KMT2AOPRM1
SCHEMBL6521358 0.89 NR1H3 (0.57) NR1H3CCR5KMT2ANR1H2MEN1
SCHEMBL6513593 0.87 NR1H3 (0.57) NR1H3CCR5KMT2ANR1H2MEN1
SCHEMBL6510639 0.87 NR1H3 (0.61) NR1H3CCR5KMT2ANR1H2MEN1
SCHEMBL6515146 0.86 NR1H3 (0.55) NR1H3CCR5KMT2ANR1H2MEN1
SCHEMBL6520045 0.85 NR1H3 (0.53) NR1H3CCR5KMT2ANR1H2MEN1
SCHEMBL6511945 0.85 NR1H3 (0.55) NR1H3CCR5KMT2ANR1H2MEN1
SCHEMBL6563550 0.84 NR1H3 (0.54) NR1H3CCR5KMT2ANR1H2MEN1
SCHEMBL6564806 0.83 NR1H3 (0.54) NR1H3CCR5KMT2ANR1H2MEN1
SCHEMBL6565734 0.82 NR1H3 (0.55) NR1H3CCR5KMT2ANR1H2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1318976-B1 SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES USEFUL AS AGONISTS FOR LXR GLAXO GROUP LTD (GB) 2004-11-24 EP claimed
US-20040072868-A1 Substitued aminopropoxyaryl derivatives useful as agonists for lxr SMITHKLINE BEECHAM CORPORATION 2004-04-15 US claimed
JP-2004509161-A 2004-03-25 JP claimed
EP-1318976-A2 SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES USEFUL AS AGONISTS FOR LXR GLAXO GROUP LIMITED (GB) 2003-06-18 EP claimed
WO-2002024632-A2 SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES USEFUL AS AGONISTS FOR LXR GLAXO GROUP LIMITED (GB) 2002-03-28 WO claimed
US-20050282908-A1 Substituted aminopropoxyaryl derivatives useful as agonists for LXR SMITHKLINE BEECHAM CORPORATION 2005-12-22 US disclosed
EP-1318976-B1 SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES USEFUL AS AGONISTS FOR LXR GLAXO GROUP LTD (GB) 2004-11-24 EP disclosed
US-20040072868-A1 Substitued aminopropoxyaryl derivatives useful as agonists for lxr SMITHKLINE BEECHAM CORPORATION 2004-04-15 US disclosed
EP-1318976-A2 SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES USEFUL AS AGONISTS FOR LXR GLAXO GROUP LIMITED (GB) 2003-06-18 EP disclosed
WO-2002024632-A2 SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES USEFUL AS AGONISTS FOR LXR GLAXO GROUP LIMITED (GB) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282908-A1 Substituted aminopropoxyaryl derivatives useful as agonists for LXR NR1H3, NR1H2, NR1H4 NR1H3 1/4885CCR5 607/4885KCNH2 4446/4885
US-20040072868-A1 Substitued aminopropoxyaryl derivatives useful as agonists for lxr NR1H2, NR1H3, NR1H4 NR1H3 2/4885CCR5 922/4885KCNH2 4495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.